Simvastatin attenuates ventilator-induced lung injury in mice

Table 1 Simvastatin treatment reduced IL-12p40 levels in plasma

	NV		NV + Simva		6 h Vent.		6 h Vent. + Simva
	mean (pg/μl)	SD	mean (pg/μl)	SD	mean (pg/μl)	SD	mean (pg/μl)	SD
IL-1β	445.30	100.70	505.30	52.19	763.2 ***	95.38	738.8 ###	100.40
IL-6	57.58	62.99	133.40	90.38	915.3 ***	459.00	993.9 ###	364.60
IL-12p40	462.10	99.32	593.10	128.60	2,352 ***	783.40	1,785 ###, ^a	372.50
MIP-1α	307.20	149.10	386.50	78.94	918.6 ***	318.60	900.8 ###	128.20
MIP-2	15.28	35.02	10.03	9.42	95.32 **	49.21	67.25 #	23.73
MCP-1	99.84	17.33	153.50	29.41	758.9 *	404.90	559.70	133.30

Cytokine levels were assessed in blood plasma after 6 h mechanical ventilation (MV) of simvastatin (6 h Vent + Simva) or sham treated mice (6 h Vent.) and in plasma of non-ventilated simvastatin (NV + Simva) or sham (NV) treated mice. MV induced a systemic inflammatory response indicated by elevated cytokine levels in blood. Simvastatin treatment reduced IL-12p40 levels in plasma significantly. The levels of IL-1β, MIP-1α, IL-6, MIP-2 and MCP-1 in VILI did not show statistically significant alterations due to simvastatin treatment. (n = 8 each group; * P < 0.05, ** P < 0.01, *** P < 0.001 vs. NV; # P < 0.05, ### P < 0.001 vs. NV + Simva; ^a P < 0.05 vs. 6 h Vent.).

ISSN: 1364-8535